Due to the placental,
endothelial, and metabolic defects (including those of folate
metabolism) leading to increased risk of developing PE, a
high dose of folic acid supplementation may be required. In
our birth cohort data, the limited number of women with
a supplementation of >2.0mg prevented us from further
grouping them into higher dose groups; however, there is
likely a continued linear relationship between folic acid dose
and reduced PE risk at doses >2.0mg